| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Cutting Edge |
-o-methyl)-Fluoromethylketone1
*
Keratinocyte Laboratory, Imperial Cancer Research Fund, London, United Kingdom;
Department of Medicine and Therapeutics, University College Dublin, Dublin, Ireland; and
Department of Histopathology, Imperial College of Science, Technology, and Medicine, London, United Kingdom
Systemic lupus erythematosus (SLE) is a common,
potentially fatal, non-organ-specific autoimmune disorder. Immune
complex-mediated kidney disease is the major cause of mortality.
Apoptotic cells in the epidermis are a possible source of self Ags, and
apoptosis of endothelial cells and lymphocytes is thought to
contribute to end-organ damage. We have previously shown that female
transgenic mice expressing IFN-
in the epidermis develop
inflammatory skin disease and features of SLE that have striking
parallels with the human condition. We have now tested the effects
of a pan-caspase inhibitor,
carbobenzoxy-valyl-alanyl-aspartyl-(
-o-methyl)-fluoromethylketone,
on disease progression. Daily s.c. administration of
carbobenzoxy-valyl-alanyl-aspartyl-(-o-methyl)-fluoromethylketone
to female transgenic mice over a 3-wk period resulted in significant
amelioration of both glomerular and interstitial renal damage,
independent of the effects on autoantibody levels or skin inflammation.
We propose that apoptosis inhibitors could be beneficial in the
treatment of human SLE.
This article has been cited by other articles:
|
|
 |
|
  A. Sharabi, D. Luger, H. Ben-David, M. Dayan, H. Zinger, and E. Mozes The Role of Apoptosis in the Ameliorating Effects of a CDR1-Based Peptide on Lupus Manifestations in a Mouse Model J. Immunol., October 15, 2007; 179(8): 4979 - 4987. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S.-M. Ka, H.-K. Sytwu, D.-M. Chang, S.-L. Hsieh, P.-Y. Tsai, and A. Chen Decoy Receptor 3 Ameliorates an Autoimmune Crescentic Glomerulonephritis Model in Mice J. Am. Soc. Nephrol., September 1, 2007; 18(9): 2473 - 2485. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. A. Emamaullee, L. Stanton, C. Schur, and A.M. J. Shapiro Caspase Inhibitor Therapy Enhances Marginal Mass Islet Graft Survival and Preserves Long-Term Function in Islet Transplantation Diabetes, May 1, 2007; 56(5): 1289 - 1298. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Krishnan, J. G. Kiang, C. U. Fisher, M. P. Nambiar, H. T. Nguyen, V. C. Kyttaris, B. Chowdhury, V. Rus, and G. C. Tsokos Increased Caspase-3 Expression and Activity Contribute to Reduced CD3{zeta} Expression in Systemic Lupus Erythematosus T Cells J. Immunol., September 1, 2005; 175(5): 3417 - 3423. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Bao, I. Osawe, M. Haas, and R. J. Quigg Signaling through Up-Regulated C3a Receptor Is Key to the Development of Experimental Lupus Nephritis J. Immunol., August 1, 2005; 175(3): 1947 - 1955. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. T. Waters, M. McDuffie, H. Bagavant, U. S. Deshmukh, F. Gaskin, C. Jiang, K. S.K. Tung, and S. M. Fu Breaking Tolerance to Double Stranded DNA, Nucleosome, and Other Nuclear Antigens Is Not Required for the Pathogenesis of Lupus Glomerulonephritis J. Exp. Med., January 20, 2004; 199(2): 255 - 264. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Schiffer, J. Sinha, X. Wang, W. Huang, G. von Gonsdorff, M. Schiffer, M. P. Madaio, and A. Davidson Short Term Administration of Costimulatory Blockade and Cyclophosphamide Induces Remission of Systemic Lupus Erythematosus Nephritis in NZB/W F1 Mice by a Mechanism Downstream of Renal Immune Complex Deposition J. Immunol., July 1, 2003; 171(1): 489 - 497. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Zhang, B. O'Brien, J. Trudeau, R. Tan, P. Santamaria, and J. P. Dutz In Situ {beta} Cell Death Promotes Priming of Diabetogenic CD8 T Lymphocytes J. Immunol., February 1, 2002; 168(3): 1466 - 1472. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
